Skip to content

Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial

Benjamin R. Lewis, Kevin Byrne, John Hendrick, Eric L Garland, Paul Thielking, Anna C. Beck

Journal of Psychedelic Studies January 18, 2023 DOI: 10.1556/2054.2022.00222 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Open-label feasibility and safety pilot study Qualitative Peer reviewed
Population Patients with a DSM-5 depressive disorder associated with a cancer diagnosis
Intervention Psilocybin-enhanced group therapy
Dose 25 mg
Topics Anxiety Psilocybin Psychedelic-assisted therapy
Keywords Psychological intervention Distress Clinical trial Group psychotherapy Referral Psychotherapist Clinical psychology
Citations 22
Key points Qualitative data from participants and therapists provide guidelines for implementing group-based psilocybin-assisted therapy, though primary clinical outcomes are still being collected.

Abstract

Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential distress associated with serious medical illness and has generally been employed on an individual basis, which presents challenges for scaling and resource availability. There are also compelling theoretical reasons to suggest that group-based formats-if utilized in a thoughtful fashion-might offer unique or enhanced therapeutic benefits for certain conditions or populations. The HOPE trial is an IRB-approved open-label feasibility and safety pilot study of psilocybin enhanced group therapy in patients with a DSM-5 depressive disorder associated with a cancer diagnosis completed at the Huntsman Cancer Institute (HCI) in Salt Lake City, Utah (HOPE: A Pilot Study of Psilocybin Enhanced Group Psychoth e rapy in Patients with Cancer). We report here qualitative survey-based data, impressions, and suggestions for group-based psychedelic-assisted therapy interventions based on our observations to inform future studies.

Methods: Patients with a DSM-5 depressive disorder with an underlying cancer diagnosis were recruited from HCI by referral from oncology providers, palliative care, and social work. Following screening and consenting, 4-6 participants per cohort (with three total cohorts) were enrolled in a protocol involving 3 120 min group preparatory sessions, a single high-dose (25 mg) group psilocybin session, and 3 subsequent group integration sessions. Primary clinical outcomes are still in process of data collection and analysis. Qualitative data was gathered from patient written reports and a survey administered at 2 weeks post intervention. Qualitative reports were also gathered from the therapist team at a post-study group process session.

Findings: We report here results from a qualitative survey of participant experiences with group format study design, as well as impressions and guidelines for group format and group psychotherapeutic process to inform other studies pursuing group-based interventions in psychedelic therapy. Suggestions are provided for protocol design, screening processes, space considerations, therapist team structure, group process, music, timeline, as well as potential issues and challenges.

Comparable studies

Other non-randomized and open-label trials on psilocybin and psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Patients with major depressive disorder 2021 Open-label study n = 24
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. Cancer patients with a DSM-5 depressive disorder (major depressive disorder or... 2023 Open-label feasibility and safety pilot study n = 12
Group psychedelic therapy: empirical estimates of cost-savings and improved access Adults with PTSD or major depressive disorder eligible for psychedelic-assisted therapy... 2023 Comparative cost analysis using trial data and published estimates
Increased low-frequency brain responses to music after psilocybin therapy for depression. Patients with treatment-resistant depression 2023 Open-label trial n = 19

Explore topics

By condition and practice